Therapeutic roles of CAR T cells in infectious diseases: Clinical lessons learnt from cancer. (17th January 2022)

• Record Type: Journal Article
• Authors: Mohammadi, Mahsa; Akhoundi, Maryam; Malih, Sara; Mohammadi, Ali; Sheykhhasan, Mohsen
• Is Part Of: Reviews in medical virology. Volume 32:Number 4(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-01-17
• Subjects: cancer -- CAR T cells -- infectious diseases; Medical virology -- Periodicals; Review Literature -- Periodicals; Virus Diseases -- Periodicals; Viruses -- Periodicals; 616.0194
• DOI: 10.1002/rmv.2325
• Languages: English
• ISSNs: 1052-9276

Abstract

Abstract: Cancer immunotherapy has made improvements due to the advances in chimaeric antigen receptor (CAR) T cell development, offering a promising treatment option for patients who have failed to respond to traditional treatments. In light of the successful use of adoptive CAR T cell therapy for cancer, researchers have been inspired to develop CARs for the treatment of other diseases beyond cancers such as viral infectious diseases. Nonetheless, various obstacles limit the efficacy of CAR T cell therapies and prevent their widespread usage. Severe toxicities, poor in vivo persistence, antigen escape, and heterogeneity, as well as off‐target effect, are key challenges that must all be addressed to broaden the application of CAR T cells to a wider spectrum of diseases. The key advances in CAR T cell treatment for cancer and viral infections are reviewed in this article. We will also discuss revolutionary CAR T cell products developed to improve and enhance the therapeutic advantages of these treatments.